Canadian Society of Transplantation Consensus Workshop on Cytomegalovirus Management in Solid Organ Transplantation Final Report

The Canadian Society of Transplantation sponsored a Cytomegalovirus (CMV) Consensus Working Group that met on March 19, 2003. The objectives of this group were to determine the current burden of CMV‐associated disease in the setting of solid organ transplantation in Canada, make recommendations regarding optimal strategies for the diagnosis, treatment and prevention of CMV infection and disease, highlight gaps in knowledge and outline priorities for research and other initiatives that might further reduce the burden of CMV‐associated effects in this setting. This report summarizes the recommendations of the working group including ratings of the strength of evidence supporting the recommendations.

[1]  B. Alexander,et al.  Efficacy and Safety of Valganciclovir vs. Oral Ganciclovir for Prevention of Cytomegalovirus Disease in Solid Organ Transplant Recipients , 2004, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[2]  M. Boeckh,et al.  Immunosuppressive effects of beta-herpesviruses. , 2003, Herpes : the journal of the IHMF.

[3]  M. Schnitzler,et al.  The Association of Cytomegalovirus Sero‐Pairing with Outcomes and Costs Following Cadaveric Renal Transplantation Prior to the Introduction of Oral Ganciclovir CMV Prophylaxis , 2003, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[4]  Guy Boivin,et al.  Cytomegalovirus (CMV) virus load kinetics to predict recurrent disease in solid-organ transplant patients with CMV disease. , 2002, The Journal of infectious diseases.

[5]  N. Singh.  Delayed Occurrence of Cytomegalovirus Disease in Organ Transplant Recipients Receiving Antiviral Prophylaxis: Are We Winning the Battle Only to Lose the War? , 2002, European Journal of Clinical Microbiology and Infectious Diseases.

[6]  E. Mylonakis,et al.  Combination antiviral therapy for ganciclovir-resistant cytomegalovirus infection in solid-organ transplant recipients. , 2002, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[7]  P. Griffiths,et al.  Definitions of cytomegalovirus infection and disease in transplant recipients. , 2002, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[8]  Thomas F. Smith,et al.  Preemptive use of oral ganciclovir to prevent cytomegalovirus infection in liver transplant patients: a randomized, placebo-controlled trial. , 2002, The Journal of infectious diseases.

[9]  Thomas F. Smith,et al.  Role of the Laboratory in Diagnosis and Management of Cytomegalovirus Infection in Hematopoietic Stem Cell and Solid-Organ Transplant Recipients , 2002, Journal of Clinical Microbiology.

[10]  C. Payá,et al.  Prophylaxis for CMV should now replace pre‐emptive therapy in solid organ transplantation , 2001, Reviews in medical virology.

[11]  V. Emery.  Prophylaxis for CMV should not now replace pre‐emptive therapy in solid organ transplantation , 2001, Reviews in medical virology.

[12]  M. Green,et al.  Preemptive therapy of cytomegalovirus disease in pediatric transplant recipients. , 2000, The Pediatric infectious disease journal.

[13]  A. Limaye,et al.  Emergence of ganciclovir-resistant cytomegalovirus disease among recipients of solid-organ transplants , 2000, The Lancet.

[14]  C. Sabin,et al.  Application of viral-load kinetics to identify patients who develop cytomegalovirus disease after transplantation , 2000, The Lancet.

[15]  T. F. Smith,et al.  Cytomegalovirus (CMV) DNA load predicts relapsing CMV infection after solid organ transplantation. , 2000, The Journal of infectious diseases.

[16]  T. Merigan,et al.  Impact of prophylactic immediate posttransplant ganciclovir on development of transplant atherosclerosis: a post hoc analysis of a randomized, placebo-controlled study. , 1999, Circulation.

[17]  J. Squifflet,et al.  Valacyclovir for the prevention of cytomegalovirus disease after renal transplantation. International Valacyclovir Cytomegalovirus Prophylaxis Transplantation Study Group. , 1999, The New England journal of medicine.

[18]  R. Rubin,et al.  Infection in organ-transplant recipients. , 1998, The New England journal of medicine.

[19]  K. Holmes,et al.  USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus: introduction. USPHS/IDSA Prevention of Opportunistic Infections Working Group. , 1995, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[20]  H. Volk,et al.  Late-acute renal allograft rejection and symptomless cytomegalovirus infection. , 1994, Lancet.

[21]  B. Griffith,et al.  Analysis of time-dependent risks for infection, rejection, and death after pulmonary transplantation. , 1995, The Journal of thoracic and cardiovascular surgery.

[22]  USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus: a summary. , 1995, MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports.